{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:52:41Z","timestamp":1793303561203,"version":"4.5.0"},"reference-count":76,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":9331,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1986,7,8]]},"abstract":"<jats:p>Aztreonam is a new, totally synthetic beta\u2010lactamase agent \u2014 the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid\u2010mediated (except PSE\u20102 enzyme found in some <jats:italic>Pseudomonas<\/jats:italic> species) or chromosomally mediated beta\u2010lactamases (except for K1 produced by rare strains of <jats:italic>Klebsiella oxytoca<\/jats:italic>). Accordingly, aztreonam remains active against many pathogens that are resistant to other beta\u2010lactam antibiotics. The drug exhibits directed antibacterial activity against gram\u2010negative organisms and is effective as monotherapy against most Enterobacteriaceae and <jats:italic>Hemophilus<\/jats:italic> and <jats:italic>Neisseria<\/jats:italic> species, including beta\u2010lactamase\u2010producing strains; it is not active against anaerobes or gram\u2010positive organisms. Before culture results are known, it may be necessary to administer the agent empirically in combination with other antibiotics. Aztreonam is rapidly distributed to most body tissues and fluids when administered parenterally. Its serum half\u2010life is 1.7 hours, suggesting a dosing interval of 6\u20138 hours for severe or life\u2010threatening infections and 8\u201312 hours for moderately severe infections and urinary tract infections. It is primarily eliminated unchanged in the urine and in much lesser amounts as a microbiologically inactive metabolite; slight biliary excretion may occur. Aztreonam is well\u2010tolerated, lacking any serious adverse hematologic, otic, or renal system effects. Its lack of effect on anaerobes helps to maintain resistance against colonization. Particularly in light of its safety and unique properties, aztreonam promises to be a useful alternative to aminoglycoside therapy.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1986.tb03468.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T19:59:34Z","timestamp":1450295974000},"page":"138-149","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Aztreonam"],"prefix":"10.1002","volume":"6","author":[{"given":"Stacy J.","family":"Childs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald P.","family":"Bodey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.1.85"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.2.294"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1128\/AAC.22.5.832","article-title":"In vitro activity of aztreonam, a monobactam antibiotic","volume":"22","author":"Jacobus NV","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_5_2","first-page":"325","article-title":"In vitro activity of aztreonam (SQ 26776), a new monobactam antibiotic","volume":"9","author":"Paradelis AG","year":"1983","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_1_6_2","volume-title":"In vitro evaluation of aztreonam","author":"Collaborative Antimicrobial Susceptibility Testing Group.","year":"1983"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808501900301"},{"issue":"1","key":"e_1_2_1_8_2","first-page":"14","article-title":"Comparative antibacterial activity of aztreonam and other antimicrobial agents against gram\u2010negative microorganisms","volume":"4","author":"Paradelis AG","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S594"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90196-2"},{"issue":"1","key":"e_1_2_1_11_2","first-page":"5","article-title":"Aztreonam: development and antibacterial properties","volume":"4","author":"Bonner DP","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_12_2","first-page":"47","volume-title":"New beta\u2010lactam antibiotics: a review from chemistry to clinical efficacy of the new cephalosporins. Vol. 1. Symposia on frontiers of clinical pharmacology","author":"Bush K","year":"1982"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.2.294"},{"key":"e_1_2_1_14_2","unstructured":"TanakaSK BonnerDP SykesRB.In vitro activity of aztreonam in combination with aminoglycosides and other beta\u2010lactams against gram\u2010positive and gram\u2010negative bacteria. Vol. 3. In:SpitzyKH KarrerK eds. Proceedings of the thirteenth international congress of chemotherapy Vienna.1983:1\u20135."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.2.279"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.2.283"},{"key":"e_1_2_1_17_2","unstructured":"RehmSJ AlanisA HallGet al.Synergism between aztreonam and tobramycin moxalactam and piperacillin againstPseudomonas aeruginosaandSerratia marcescens. Vol. 3 In:SpitzyKH KarrerK eds. Proceedings of the thirteenth international congress of chemotherapy Vienna.1983:8\u201312."},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.4.634"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.6.968"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/8.suppl_E.131"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.1.125"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.1.16"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.1.125"},{"key":"e_1_2_1_24_2","first-page":"35","article-title":"Review of the clinical pharmacology of aztreonam","volume":"4","author":"Swabb EA.","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_25_2","volume-title":"Drug therapy","author":"Barza M","year":"1983"},{"key":"e_1_2_1_26_2","first-page":"1","article-title":"The third\u2010generation cephalosporins. II","volume":"16","author":"Beam TR.","year":"1982","journal-title":"Ration Drug Ther"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.3.394"},{"key":"e_1_2_1_28_2","unstructured":"SwabbEA.Human pharmacology of aztreonam. In:SpitzyKH KarrerK eds. Proceedings of the thirteenth international congress of chemotherapy Vienna.1983."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.6.944"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.82"},{"issue":"2","key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9343(85)90197-4","article-title":"Review of the clinical pharmacology of the monobactam antibiotic aztreonam","volume":"78","author":"Swabb EA.","year":"1985","journal-title":"Am J Med"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.2.252"},{"key":"e_1_2_1_33_2","unstructured":"SattlerFR SchrammM SwabbEA.Safety of aztreonam and SQ 26 992 in elderly patients with renal insufficiency. To be published."},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510010-00005"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1984.174"},{"key":"e_1_2_1_36_2","unstructured":"BoltonND GerigJ ScheldWMet al.Pharmacokinetics of aztreonam in patients on chronic ambulatory peritoneal dialysis. In:SpitzyKH KarrerK eds. Proceedings of the thirteenth international congress of chemotherapy Vienna.1983."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.3.358"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.4.493"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1984.tb01827.x"},{"issue":"2","key":"e_1_2_1_40_2","first-page":"127","article-title":"Aztreonam vs cefamandole in the treatment of urinary tract infections","volume":"3","author":"Giamarellou H","year":"1984","journal-title":"Chemotherapia"},{"issue":"6","key":"e_1_2_1_41_2","first-page":"385","article-title":"Comparative study of aztreonam and cefamandole in the treatment of serious urinary tract infections","volume":"5","author":"Tsouroutsoglou W","year":"1983","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"1","key":"e_1_2_1_42_2","first-page":"113","article-title":"Randomized comparative study of aztreonam and cefamanodole in the treatment of urinary tract infection","volume":"36","author":"Webb DW","year":"1984","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91817-8"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.2.245"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90203-7"},{"key":"e_1_2_1_46_2","first-page":"46","article-title":"Aztreonam therapy of complicated urinary tract infections due to multidrug\u2010resistant bacteria","volume":"4","author":"Cox CE.","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_47_2","first-page":"51","article-title":"Multicentre study in patients with urinary tract infections treated with aztreonam","volume":"4","author":"Martelli A","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_48_2","first-page":"56","article-title":"Experience with some new antibiotics in urinary tract infections","volume":"4","author":"Sabbour MS","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_49_2","first-page":"61","article-title":"Bacteriological and clinical evaluation of aztreonam in urinary tract infections in hospitalized patients","volume":"4","author":"Agabiti\u2010Rosei E","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/148.3.612"},{"key":"e_1_2_1_51_2","first-page":"31","article-title":"Aztreonam in patients with acute gonococcal urethritis","volume":"118","author":"Negosanti M","year":"1983","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.2.270"},{"key":"e_1_2_1_53_2","first-page":"102","article-title":"Aztreonam: worldwide clinical trials results","volume":"4","author":"Bendush CL","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S696"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S724"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.2.246"},{"key":"e_1_2_1_57_2","unstructured":"NolenTM PhillipsHL HallHJ.A comparison of aztreonam and tobramycin in the treatment of gram\u2010negative lower respiratory infections. To be published."},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90201-3"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S669"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S783"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90205-0"},{"key":"e_1_2_1_62_2","first-page":"67","article-title":"Clinical evaluation of aztreonam in gram\u2010negative septicemia","volume":"4","author":"Gudiol F.","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_63_2","first-page":"70","article-title":"Aztreonam in severe gram\u2010negative septicemia","volume":"4","author":"Cran S","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S836"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S831"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S810"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S741"},{"key":"e_1_2_1_68_2","first-page":"110","article-title":"Microbiological and clinical evaluation of aztreonam in immunocompromised hosts","volume":"4","author":"Cipriani P","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90435-8"},{"key":"e_1_2_1_70_2","unstructured":"Garcia\u2010RodriguezJA CapurroM FrietoJ.The use of aztreonam in high risk patients in the intensive care unit. In:SpitzyKH KarrerK eds. Proceedings of the thirteenth internatl congress of chemotherapy Vienna.1983:48\u201352."},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.2.280"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.1.93"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S613"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.1.16"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.6.941"},{"key":"e_1_2_1_76_2","first-page":"107","article-title":"Effect of aztreonam plus cloxacillin, aztreonam plus tobramycin or moxalactam plus tobramycin and colonization resistance parameters during empiric therapy of febrile neutropenic episodes","volume":"4","author":"Louie TJ","year":"1985","journal-title":"Chemotherapia"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.Supplement_4.S628"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1986.tb03468.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1986.tb03468.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1986.tb03468.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:47:39Z","timestamp":1761054459000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1986.tb03468.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,7,8]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1986,7,8]]}},"alternative-id":["10.1002\/j.1875-9114.1986.tb03468.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1986.tb03468.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,7,8]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}